

Vaccine Supply Update

Advisory Committee on Immunization Practices

Atlanta, GA
June 21, 2018

Jeanne M. Santoli
Immunization Services Division
National Center for Immunization and Respiratory Diseases



DEPARTMENT OF HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE CONTROL AND PREVENTION



SAFER · HEALTHIER · PEOPLE

Outline

- Hepatitis A Supply Update
- Hepatitis B Supply Update
 - Adult
 - Pediatric
- CDC Vaccine Supply/Shortage Page

Adult Hepatitis A Vaccine

- During 2017, large outbreaks of hepatitis A among adults in several US cities resulted in increased demand for vaccine and constrained supply.
- Actions taken included collaboration between CDC and public health officials in affected jurisdictions to target vaccine based on local epidemiology; implementation of ordering controls to maintain an equitable distribution of vaccine in unaffected jurisdictions; and modification of CDC's vaccine contracts to support additional vaccine purchase.
- In addition, both GSK and Merck have increased the amount of vaccine available in the US market for outbreaks and routine use.

Adult Hepatitis A Vaccine, II

- Vaccine continues to be directed toward jurisdictions with outbreaks. In addition, as vaccine supplies have improved, the vaccine supply strategy has evolved, making more vaccine available for routine use and/or prevention activities in jurisdictions without large, ongoing outbreaks.
- CDC and vaccine manufacturers are continuing to monitor ongoing demand for and usage of adult hepatitis A vaccine closely.

Adult Hepatitis B Vaccine

- Merck is not currently distributing its adult hepatitis B vaccine or dialysis formulation and will not be distributing vaccine through the end of 2018.
- GSK has sufficient supply of adult hepatitis B vaccine to address the anticipated gap in Merck's adult hepatitis B vaccine supply during this period; however, preferences for a specific presentation (i.e., vial versus syringe) may not be met uniformly during this time.

Pediatric Hepatitis B Vaccine

- Merck has not been distributing its pediatric hepatitis B vaccines since mid-2017 and will continue to have a limited supply of pediatric hepatitis B vaccine during 2018.
- Together, both manufacturers (Merck and GSK) are able to supply the US market with approximately 10% less monovalent pediatric hepatitis B vaccine than normal during 2018.
- This expected monovalent supply is sufficient to cover the birth dose for all children as well as additional vaccine for some second and third doses.

Pediatric Hepatitis B Vaccine, II

- CDC has implemented controlled vaccine ordering in the public sector using both Merck's and GSK's monovalent vaccines.
- In addition, GSK is providing monovalent vaccine to the private sector aligned with with CDC's clinical guidance.
- GSK's DTaP-HepB-IPV combination vaccine (Pediatrix) continues to be available in the public and private sectors.

CDC's Vaccine Supply/Shortage Webpage

- Available at:
<https://www.cdc.gov/vaccines/hcp/clinical-resources/shortages.html>